Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The operational activity ratios indicate a general decline in efficiency regarding asset utilization and cash flow velocity over the analyzed period. The most significant trend is the expansion of the operating and cash conversion cycles, primarily driven by a slowdown in inventory turnover.
- Inventory Management
- Inventory turnover has exhibited a gradual downward trend, decreasing from 4.50 in early 2022 to 3.28 by September 2026. Correspondingly, the average inventory processing period has lengthened from 81 days to 111 days. This suggests a slower movement of stock and an increase in the duration that capital remains tied up in inventory.
- Receivables Management
- Receivables turnover has remained relatively stable, fluctuating within a range of 5.60 to 7.18. The average receivable collection period has shown minimal volatility, generally oscillating between 51 and 65 days. This indicates a consistent and predictable approach to credit collection and revenue realization.
- Payables and Working Capital
- Payables turnover shows significant volatility, with sharp fluctuations between a high of 12.57 and a low of 6.25. The average payables payment period varies widely, ranging from 29 to 58 days, suggesting inconsistent payment strategies or shifting vendor terms. Working capital turnover has been highly erratic, characterized by extreme spikes—most notably reaching 84.15 in June 2023—followed by a return to lower levels, indicating periods of significant volatility in the relationship between current assets, liabilities, and revenue.
- Operational Cycles
- The operating cycle has extended from 132 days in March 2022 to 170 days by September 2026, reflecting the cumulative impact of slower inventory turnover. The cash conversion cycle has followed a similar upward trajectory, rising from 100 days to 115 days, with a peak of 143 days in June 2024. This extension signifies that the company takes longer to convert its investments in inventory and receivables back into cash.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Inventory Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of goods sold | 1,571) | 1,579) | 1,445) | 1,624) | 1,569) | 1,501) | 1,540) | 1,581) | 1,574) | 1,544) | 1,552) | 2,090) | 1,565) | 1,442) | 1,401) | 1,396) | 1,395) | 1,442) | 1,424) | ||||||
| Inventories | 1,896) | 1,953) | 1,914) | 1,774) | 1,785) | 1,825) | 1,759) | 1,710) | 1,869) | 2,026) | 1,853) | 1,787) | 1,663) | 1,633) | 1,576) | 1,507) | 1,463) | 1,494) | 1,482) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | 3.28 | 3.18 | 3.21 | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 3.27 | 3.58 | 3.65 | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Amgen Inc. | 1.77 | 1.87 | 1.91 | 1.93 | 1.92 | 1.88 | 1.88 | 1.84 | 1.75 | 1.42 | 1.14 | 0.89 | 1.41 | 1.38 | 1.31 | 1.30 | 1.34 | 1.40 | 1.48 | ||||||
| Bristol-Myers Squibb Co. | 5.69 | 5.36 | 5.20 | 5.18 | 5.31 | 5.18 | 5.28 | 5.46 | 3.57 | 3.72 | 3.70 | 4.02 | 4.33 | 4.39 | 3.93 | 4.33 | 4.77 | 4.59 | 4.55 | ||||||
| Danaher Corp. | 3.38 | 3.20 | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Eli Lilly & Co. | 0.78 | 0.79 | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Johnson & Johnson | 2.10 | 2.08 | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Merck & Co. Inc. | 3.09 | 2.90 | 2.65 | 2.46 | 2.27 | 2.25 | 2.43 | 2.49 | 2.45 | 2.39 | 2.42 | 2.54 | 2.63 | 2.66 | 2.72 | 2.95 | 3.10 | 3.06 | 2.74 | ||||||
| Pfizer Inc. | 1.69 | 1.72 | 1.57 | 1.51 | 1.46 | 1.52 | 1.60 | 1.65 | 1.66 | 2.05 | 2.15 | 2.45 | 2.65 | 2.31 | 3.07 | 3.82 | 3.62 | 3.66 | 3.67 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.83 | 0.76 | 0.74 | 0.66 | 0.64 | 0.64 | 0.63 | 0.64 | 0.64 | 0.65 | 0.66 | 0.70 | 0.72 | 0.69 | 0.67 | 0.65 | 0.83 | 0.96 | 1.27 | ||||||
| Thermo Fisher Scientific Inc. | 4.94 | 4.87 | 4.87 | 4.85 | 4.47 | 4.57 | 4.82 | 5.06 | 4.62 | 4.83 | 4.93 | 5.06 | 4.83 | 4.64 | 4.62 | 4.60 | 4.29 | 4.03 | 3.87 | ||||||
| Vertex Pharmaceuticals Inc. | 0.83 | 1.00 | 0.95 | 0.98 | 0.99 | 1.06 | 1.14 | 1.27 | 1.37 | 1.53 | 1.65 | 1.71 | 1.71 | 1.90 | 2.06 | 2.35 | 2.69 | 2.70 | 2.83 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Inventory turnover
= (Cost of goods soldQ3 2026
+ Cost of goods soldQ2 2026
+ Cost of goods soldQ1 2026
+ Cost of goods soldQ4 2025)
÷ Inventories
= (1,571 + 1,579 + 1,445 + 1,624)
÷ 1,896 = 3.28
2 Click competitor name to see calculations.
The analysis of operating activity reveals a consistent long-term decline in inventory turnover efficiency. Over the period from March 2022 to September 2026, the turnover ratio transitioned from a peak of 4.71 to a low of 3.18, signaling a slowdown in the rate at which inventory is sold and replaced.
- Inventory Level Trends
- Inventory balances exhibited a general upward trajectory, increasing from 1,482 million USD in March 2022 to a peak of 2,026 million USD in June 2024. While there was a temporary correction toward the end of 2024, inventory levels remained elevated throughout 2025 and 2026, consistently staying above 1,700 million USD. This growth in stored assets without a proportional increase in sales volume contributed to the overall reduction in turnover efficiency.
- Cost of Goods Sold (COGS) Volatility
- The cost of goods sold remained relatively stable for much of the period, typically fluctuating between 1,400 million USD and 1,600 million USD per quarter. A significant outlier occurred in December 2023, where COGS spiked to 2,090 million USD. This surge provided a temporary boost to the turnover ratio during that specific quarter, though it did not alter the broader downward trend.
- Inventory Turnover Ratio Performance
- The inventory turnover ratio can be divided into three distinct phases. Initially, from March 2022 to September 2022, the company maintained high efficiency with ratios between 4.50 and 4.71. A period of deterioration followed between December 2022 and June 2023, where the ratio dropped toward the 3.45 range. The final phase, spanning 2025 and 2026, shows a further decline to a baseline between 3.18 and 3.28, indicating that inventory is held longer before being converted into sales.
The convergence of rising inventory levels and stagnant cost of goods sold indicates a decreasing operational velocity. The transition from a turnover ratio of 4.71 to 3.28 suggests that the company is carrying more stock relative to its sales requirements than it did at the start of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Receivables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Product sales | 8,289) | 7,627) | 6,946) | 7,903) | 7,345) | 7,054) | 6,613) | 7,536) | 7,515) | 6,912) | 6,647) | 7,070) | 6,994) | 6,564) | 6,306) | 7,332) | 6,978) | 6,138) | 6,534) | ||||||
| Accounts receivable, net | 5,007) | 5,055) | 4,741) | 4,913) | 5,095) | 4,781) | 4,388) | 4,420) | 4,587) | 4,663) | 4,669) | 4,660) | 4,790) | 4,229) | 4,162) | 4,777) | 4,354) | 4,118) | 3,787) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 6.14 | 5.90 | 6.17 | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 4.89 | 4.66 | 5.03 | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Amgen Inc. | 3.57 | 3.55 | 3.88 | 3.67 | 4.06 | 3.85 | 4.03 | 4.72 | 4.26 | 4.26 | 4.16 | 3.70 | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | ||||||
| Danaher Corp. | 6.21 | 6.33 | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Eli Lilly & Co. | 3.91 | 3.97 | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Johnson & Johnson | 5.23 | 5.14 | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Merck & Co. Inc. | 5.29 | 5.30 | 5.39 | 5.52 | 5.30 | 5.37 | 5.92 | 6.24 | 5.55 | 5.37 | 5.40 | 5.81 | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | ||||||
| Pfizer Inc. | 4.48 | 5.10 | 5.03 | 5.27 | 4.40 | 5.29 | 5.27 | 5.55 | 4.18 | 4.93 | 5.09 | 5.33 | 6.25 | 7.66 | 7.57 | 9.16 | 6.21 | 6.68 | 6.99 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.23 | 2.37 | 2.60 | 2.50 | 2.51 | 2.53 | 2.53 | 2.29 | 2.27 | 2.36 | 2.51 | 2.31 | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | ||||||
| Thermo Fisher Scientific Inc. | 4.92 | 4.90 | 4.91 | 5.01 | 4.91 | 5.03 | 5.07 | 5.23 | 5.13 | 5.33 | 5.36 | 5.21 | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | ||||||
| Vertex Pharmaceuticals Inc. | 5.60 | 5.90 | 6.12 | 5.85 | 6.02 | 6.03 | 6.15 | 6.85 | 6.07 | 6.24 | 5.68 | 6.31 | 6.27 | 6.11 | 5.95 | 6.19 | 6.28 | 6.26 | 6.15 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Receivables turnover
= (Product salesQ3 2026
+ Product salesQ2 2026
+ Product salesQ1 2026
+ Product salesQ4 2025)
÷ Accounts receivable, net
= (8,289 + 7,627 + 6,946 + 7,903)
÷ 5,007 = 6.14
2 Click competitor name to see calculations.
The analysis of the receivables turnover ratio reveals a period of volatility characterized by cyclical fluctuations rather than a linear trend. The ratio, which measures the efficiency of converting accounts receivable into cash, peaked at 7.18 in March 2022 and reached its lowest point of 5.60 in September 2025, ending the period at 6.14 in September 2026.
- Correlation Between Sales and Receivables
- Product sales exhibited a general upward trajectory over the analyzed period, growing from 6,534 million USD in March 2022 to 8,289 million USD by September 2026. During this same interval, net accounts receivable increased from 3,787 million USD to 5,007 million USD. The fluctuations in the turnover ratio are primarily driven by the rate at which receivables grew relative to sales. For instance, the decline in the ratio during 2022 coincided with a sharp increase in net accounts receivable that outpaced the growth in product sales.
- Efficiency Cycles and Troughs
- Three distinct periods of declining efficiency are observable. The first occurred between March 2022 and December 2022, where the ratio dropped from 7.18 to 5.65. A second dip was noted in September 2023 (5.68), and a third, more pronounced decline reached a minimum of 5.60 in September 2025. These troughs typically correspond with quarters where accounts receivable balances expanded significantly relative to the quarterly sales volume, suggesting temporary delays in collections or changes in credit terms.
- Recovery Patterns
- Periods of recovery in the turnover ratio indicate improved collection efficiency or a reduction in outstanding receivables. A notable recovery occurred between December 2023 and December 2024, with the ratio climbing from 5.78 to 6.47. This improvement was supported by a reduction in net accounts receivable from 4,660 million USD to 4,420 million USD despite steady product sales, indicating a more aggressive or effective collection process during that fiscal window.
- Long-term Operating Trend
- Comparing the starting point of 7.18 in March 2022 to the ending point of 6.14 in September 2026 suggests a moderate decrease in overall receivables turnover efficiency over the long term. While product sales grew by approximately 27%, the net accounts receivable balance grew by approximately 32%, resulting in a slightly lower turnover ratio at the end of the period than at the beginning.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Payables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of goods sold | 1,571) | 1,579) | 1,445) | 1,624) | 1,569) | 1,501) | 1,540) | 1,581) | 1,574) | 1,544) | 1,552) | 2,090) | 1,565) | 1,442) | 1,401) | 1,396) | 1,395) | 1,442) | 1,424) | ||||||
| Accounts payable | 934) | 674) | 645) | 715) | 808) | 582) | 737) | 833) | 903) | 537) | 622) | 550) | 586) | 622) | 627) | 905) | 614) | 565) | 583) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | 6.66 | 9.22 | 9.52 | 8.72 | 7.66 | 10.65 | 8.47 | 7.50 | 7.49 | 12.57 | 10.69 | 11.81 | 9.90 | 9.06 | 8.99 | 6.25 | 11.22 | 11.89 | 11.43 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | 3.84 | 4.05 | 4.02 | 5.09 | 4.29 | 4.12 | 5.25 | 6.74 | 5.99 | 5.01 | 6.10 | 5.32 | 5.22 | 5.67 | 4.97 | 4.08 | 5.30 | 5.09 | 4.65 | ||||||
| Bristol-Myers Squibb Co. | 3.33 | 3.53 | 3.38 | 3.90 | 3.42 | 2.61 | 3.52 | 3.88 | 3.43 | 3.05 | 3.12 | 3.28 | 3.75 | 3.38 | 3.20 | 3.33 | 3.82 | 3.41 | 3.25 | ||||||
| Danaher Corp. | 6.09 | 5.72 | 5.68 | 5.45 | 5.78 | 5.62 | 5.57 | 5.52 | 6.04 | 5.84 | 5.88 | 5.58 | 5.63 | 5.82 | 5.68 | 5.45 | 5.61 | 5.00 | 5.04 | ||||||
| Eli Lilly & Co. | 2.44 | 2.16 | 2.47 | 2.05 | 2.37 | 2.27 | 2.61 | 2.61 | 2.70 | 2.56 | 2.88 | 2.73 | 2.81 | 2.65 | 3.07 | 3.43 | 4.24 | 4.21 | 5.24 | ||||||
| Johnson & Johnson | 3.46 | 3.41 | 2.96 | 2.52 | 3.06 | 3.07 | 2.97 | 2.66 | 3.03 | 3.03 | 3.23 | 2.76 | 3.29 | 2.75 | 3.05 | 2.66 | 3.08 | 3.15 | 3.26 | ||||||
| Merck & Co. Inc. | 3.78 | 4.70 | 4.44 | 3.72 | 3.53 | 3.82 | 3.98 | 3.72 | 4.26 | 4.39 | 4.48 | 4.11 | 4.59 | 4.58 | 4.34 | 4.08 | 5.16 | 4.86 | 4.25 | ||||||
| Pfizer Inc. | 4.16 | 3.73 | 3.72 | 3.07 | 3.32 | 3.44 | 3.30 | 3.17 | 3.67 | 4.60 | 4.19 | 3.72 | 5.07 | 3.92 | 4.78 | 5.04 | 5.49 | 6.17 | 6.66 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.11 | 2.03 | 2.24 | 2.24 | 2.30 | 2.83 | 2.84 | 2.50 | 3.87 | 3.32 | 2.67 | 2.99 | 3.43 | 3.14 | 2.69 | 2.65 | 3.74 | 4.00 | 5.39 | ||||||
| Thermo Fisher Scientific Inc. | 9.04 | 8.39 | 8.00 | 7.27 | 8.23 | 8.53 | 8.25 | 8.18 | 9.63 | 9.85 | 9.91 | 8.97 | 10.41 | 10.82 | 9.35 | 7.67 | 9.93 | 8.84 | 7.96 | ||||||
| Vertex Pharmaceuticals Inc. | 3.97 | 4.10 | 3.44 | 3.58 | 3.83 | 3.59 | 3.49 | 3.71 | 3.73 | 4.27 | 3.81 | 3.46 | 3.13 | 3.16 | 3.41 | 3.55 | 8.23 | 5.01 | 5.52 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Payables turnover
= (Cost of goods soldQ3 2026
+ Cost of goods soldQ2 2026
+ Cost of goods soldQ1 2026
+ Cost of goods soldQ4 2025)
÷ Accounts payable
= (1,571 + 1,579 + 1,445 + 1,624)
÷ 934 = 6.66
2 Click competitor name to see calculations.
The analysis of payables turnover reveals a volatile trend characterized by periodic declines that correlate closely with spikes in accounts payable balances. The ratio fluctuates between a high of 12.57 and a low of 6.25, indicating inconsistent cycles in the settlement of obligations to suppliers over the observed period.
- Payables Turnover Volatility
- A pattern of cyclical instability is evident. The ratio maintained relative stability between March 2022 and September 2022, followed by a sharp contraction to 6.25 in December 2022. While the ratio recovered to 11.81 by December 2023 and reached its peak of 12.57 in June 2024, it experienced subsequent declines in September 2024 (7.49) and September 2026 (6.66).
- Impact of Accounts Payable Fluctuations
- Significant drops in the turnover ratio are directly tied to substantial increases in accounts payable. Specifically, the lows observed in December 2022, September 2024, and September 2026 correspond with payables balances rising to 905 million, 903 million, and 934 million USD, respectively. These spikes suggest periods where the company extended its payment terms or experienced an accumulation of short-term liabilities, thereby slowing the turnover rate.
- Cost of Goods Sold (COGS) Correlation
- Cost of goods sold remained relatively stable, generally ranging between 1.4 billion and 1.6 billion USD, with a notable outlier of 2.09 billion USD in December 2023. Despite this spike in costs, the payables turnover ratio actually increased to 11.81 during that quarter, indicating that the increase in COGS was not matched by a proportional increase in accounts payable, leading to a more rapid turnover of liabilities.
- Operational Efficiency Insights
- The highest level of efficiency in clearing payables occurred in June 2024, where the ratio peaked at 12.57. Conversely, the recurring dips toward the 6.0 to 7.0 range suggest a periodic strategic or operational shift toward utilizing supplier credit for working capital management, effectively delaying cash outflows at specific quarterly intervals.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Working Capital Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | 16,553) | 13,945) | 18,641) | 18,342) | 17,874) | 14,718) | 16,901) | 19,173) | 14,779) | 12,317) | 14,041) | 16,085) | 15,980) | 14,287) | 13,456) | 14,443) | 13,554) | 13,175) | 12,629) | ||||||
| Less: Current liabilities | 12,002) | 11,020) | 9,476) | 11,813) | 12,298) | 11,189) | 12,344) | 12,004) | 11,725) | 10,781) | 13,015) | 11,280) | 11,945) | 13,964) | 10,528) | 11,237) | 10,423) | 9,220) | 8,558) | ||||||
| Working capital | 4,551) | 2,925) | 9,165) | 6,529) | 5,576) | 3,529) | 4,557) | 7,169) | 3,054) | 1,536) | 1,026) | 4,805) | 4,035) | 323) | 2,928) | 3,206) | 3,131) | 3,955) | 4,071) | ||||||
| Product sales | 8,289) | 7,627) | 6,946) | 7,903) | 7,345) | 7,054) | 6,613) | 7,536) | 7,515) | 6,912) | 6,647) | 7,070) | 6,994) | 6,564) | 6,306) | 7,332) | 6,978) | 6,138) | 6,534) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | 6.76 | 10.20 | 3.19 | 4.43 | 5.12 | 8.14 | 6.27 | 3.99 | 9.22 | 17.98 | 26.58 | 5.61 | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | 3.32 | 3.83 | 5.44 | 9.85 | 5.66 | 5.35 | 8.36 | 5.40 | 4.83 | 5.19 | 3.39 | 2.25 | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | ||||||
| Bristol-Myers Squibb Co. | 4.40 | 4.81 | 5.84 | 7.83 | 6.20 | 8.09 | 6.87 | 7.79 | 8.49 | 12.50 | 15.56 | 4.60 | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | ||||||
| Danaher Corp. | 4.46 | 4.76 | 3.83 | 4.13 | 7.39 | 5.71 | 8.27 | 8.85 | 8.73 | 8.10 | 3.60 | 4.22 | 2.18 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | ||||||
| Eli Lilly & Co. | 4.73 | 4.71 | 3.97 | 3.19 | 2.71 | 4.92 | 4.38 | 10.32 | 6.06 | 12.62 | 5.45 | — | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | ||||||
| Johnson & Johnson | 111.11 | 20.07 | 66.14 | 62.88 | 24.63 | 284.99 | 6.10 | 15.94 | 58.86 | 22.29 | 10.35 | 11.81 | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | ||||||
| Merck & Co. Inc. | 6.64 | 7.44 | 8.15 | 4.28 | 3.39 | 5.77 | 6.19 | 6.19 | 5.86 | 5.14 | 9.68 | 9.29 | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | ||||||
| Pfizer Inc. | 4.79 | 7.31 | 7.47 | 10.58 | 6.08 | 10.68 | 6.64 | 8.64 | 5,036.00 | — | 29.17 | — | 1.62 | 2.03 | 6.89 | 11.00 | 3.83 | 5.05 | 6.10 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.16 | 1.20 | 1.14 | 1.05 | 1.05 | 1.08 | 1.01 | 0.97 | 0.88 | 0.87 | 0.86 | 0.82 | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | ||||||
| Thermo Fisher Scientific Inc. | 4.14 | 5.59 | 5.87 | 3.30 | 5.90 | 3.64 | 4.20 | 4.87 | 4.61 | 3.96 | 4.38 | 4.05 | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | ||||||
| Vertex Pharmaceuticals Inc. | 1.94 | 1.46 | 1.56 | 1.64 | 1.92 | 1.82 | 1.78 | 1.83 | 1.82 | 1.92 | 1.07 | 0.93 | 0.87 | 0.90 | 0.93 | 0.85 | 0.90 | 0.93 | 0.97 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Working capital turnover
= (Product salesQ3 2026
+ Product salesQ2 2026
+ Product salesQ1 2026
+ Product salesQ4 2025)
÷ Working capital
= (8,289 + 7,627 + 6,946 + 7,903)
÷ 4,551 = 6.76
2 Click competitor name to see calculations.
The analysis of operating activity indicates a period of significant volatility in working capital management, contrasting with a steady and gradual increase in product sales. While revenue streams demonstrate consistent growth, the working capital turnover ratio fluctuates sharply, reflecting instability in the relationship between current assets and current liabilities.
- Product Sales Performance
- Revenue from product sales shows a general upward trajectory, rising from 6,534 million USD in March 2022 to 8,289 million USD by September 2026. This growth is characterized by moderate quarterly oscillations but lacks the extreme variance observed in the company's short-term asset and liability positions.
- Working Capital Volatility
- Working capital levels exhibit erratic movements throughout the analyzed period. A critical contraction occurred in June 2023, where working capital dropped to 323 million USD. This was followed by a series of expansions, peaking at 9,165 million USD in March 2026, before sharply declining again to 2,925 million USD in June 2026. These swings suggest aggressive changes in short-term financing or significant shifts in inventory and receivables management.
- Working Capital Turnover Dynamics
- The turnover ratio reflects the impact of working capital volatility. An exceptional peak of 84.15 was recorded in June 2023, directly resulting from the precipitous drop in working capital relative to stable sales. Conversely, as working capital expanded toward the end of the period, the turnover ratio declined, reaching a low of 3.19 in March 2026. This indicates a period of lower operational efficiency in utilizing working capital to generate sales.
- Operational Efficiency Trends
- Between March 2022 and March 2023, the turnover ratio trended upward from 6.68 to 9.14, suggesting improving efficiency. However, the subsequent years are marked by inconsistency. The sharp recovery of the ratio to 10.20 in June 2026, following the March 2026 low, indicates a rapid reduction in working capital, which mathematically inflates the turnover ratio regardless of underlying sales growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Inventory Processing Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | 3.28 | 3.18 | 3.21 | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | 111 | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 112 | 102 | 100 | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Amgen Inc. | 206 | 195 | 191 | 189 | 190 | 194 | 195 | 199 | 209 | 257 | 321 | 411 | 259 | 265 | 279 | 281 | 272 | 260 | 247 | ||||||
| Bristol-Myers Squibb Co. | 64 | 68 | 70 | 70 | 69 | 70 | 69 | 67 | 102 | 98 | 99 | 91 | 84 | 83 | 93 | 84 | 76 | 79 | 80 | ||||||
| Danaher Corp. | 108 | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Eli Lilly & Co. | 469 | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Johnson & Johnson | 174 | 176 | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Merck & Co. Inc. | 118 | 126 | 138 | 148 | 160 | 162 | 150 | 147 | 149 | 153 | 151 | 144 | 139 | 137 | 134 | 124 | 118 | 119 | 133 | ||||||
| Pfizer Inc. | 216 | 212 | 232 | 242 | 251 | 239 | 229 | 222 | 219 | 178 | 170 | 149 | 138 | 158 | 119 | 95 | 101 | 100 | 99 | ||||||
| Regeneron Pharmaceuticals Inc. | 439 | 479 | 491 | 556 | 571 | 570 | 582 | 572 | 573 | 562 | 553 | 519 | 508 | 532 | 549 | 562 | 440 | 379 | 287 | ||||||
| Thermo Fisher Scientific Inc. | 74 | 75 | 75 | 75 | 82 | 80 | 76 | 72 | 79 | 76 | 74 | 72 | 76 | 79 | 79 | 79 | 85 | 91 | 94 | ||||||
| Vertex Pharmaceuticals Inc. | 437 | 365 | 384 | 373 | 369 | 345 | 320 | 287 | 267 | 238 | 222 | 214 | 213 | 192 | 177 | 156 | 136 | 135 | 129 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.28 = 111
2 Click competitor name to see calculations.
An analysis of the short-term operating activity indicators reveals a general decline in inventory management efficiency from March 2022 through September 2026. The inverse relationship between the inventory turnover ratio and the average inventory processing period demonstrates a consistent trend toward longer holding cycles and slower inventory liquidation.
- Inventory Turnover Ratio
- The inventory turnover ratio experienced a peak of 4.71 in September 2022 before entering a period of gradual decline. Following this peak, the ratio dropped significantly to 3.75 by December 2022 and remained largely within the 3.33 to 3.66 range throughout 2023 and 2024. A further deterioration in turnover efficiency is observed in 2026, where the ratio reached its lowest points, dipping to 3.18 in June 2026 and ending at 3.28 in September 2026.
- Average Inventory Processing Period
- The average inventory processing period shows a corresponding upward trend, indicating that goods are remaining in inventory for longer durations. The period began at 81 days in the first half of 2022 and escalated to 97 days by December 2022. Throughout 2023 and 2024, the processing period fluctuated primarily between 100 and 110 days. The most pronounced extension of the cycle occurred in the first half of 2026, peaking at 115 days in June 2026 before settling at 111 days by September 2026.
- Operational Trend Analysis
- The data suggests a systemic shift in operating activity. The transition from a processing period of approximately 80 days to a period exceeding 110 days represents a significant increase in the time capital is tied up in inventory. The stability observed between 2023 and 2025 was followed by a noticeable decrease in efficiency during the 2026 period, signaling a potential slowdown in inventory throughput or a strategic increase in safety stock levels.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Receivable Collection Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 6.14 | 5.90 | 6.17 | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 59 | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 75 | 78 | 73 | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Amgen Inc. | 102 | 103 | 94 | 99 | 90 | 95 | 91 | 77 | 86 | 86 | 88 | 99 | 88 | 84 | 84 | 82 | 79 | 79 | 76 | ||||||
| Danaher Corp. | 59 | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Eli Lilly & Co. | 93 | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Johnson & Johnson | 70 | 71 | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Merck & Co. Inc. | 69 | 69 | 68 | 66 | 69 | 68 | 62 | 58 | 66 | 68 | 68 | 63 | 64 | 69 | 66 | 58 | 59 | 62 | 66 | ||||||
| Pfizer Inc. | 81 | 72 | 73 | 69 | 83 | 69 | 69 | 66 | 87 | 74 | 72 | 69 | 58 | 48 | 48 | 40 | 59 | 55 | 52 | ||||||
| Regeneron Pharmaceuticals Inc. | 164 | 154 | 140 | 146 | 146 | 144 | 144 | 160 | 161 | 155 | 146 | 158 | 156 | 148 | 151 | 160 | 148 | 132 | 107 | ||||||
| Thermo Fisher Scientific Inc. | 74 | 74 | 74 | 73 | 74 | 73 | 72 | 70 | 71 | 68 | 68 | 70 | 70 | 67 | 66 | 66 | 63 | 66 | 70 | ||||||
| Vertex Pharmaceuticals Inc. | 65 | 62 | 60 | 62 | 61 | 61 | 59 | 53 | 60 | 58 | 64 | 58 | 58 | 60 | 61 | 59 | 58 | 58 | 59 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.14 = 59
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a fluctuating trend in the efficiency of receivable collections from March 2022 through September 2026. The data indicates a period of initial deterioration in collection efficiency followed by cycles of recovery and stabilization.
- Receivables Turnover
- A downward trajectory is observed during 2022, with the ratio declining from 7.18 in March to a low of 5.65 by December. Subsequently, the ratio experienced moderate volatility, reaching a peak of 6.51 in December 2023. From 2024 through 2026, the turnover ratio remained relatively stable, fluctuating within a narrow band between 5.60 and 6.17, ending the period at 6.14.
- Average Receivable Collection Period
- The collection period exhibits an inverse relationship with the turnover ratio, characterized by an overall increase in the time required to convert receivables into cash. The period expanded from 51 days in March 2022 to a peak of 65 days by December 2022. While efficiency improved during 2023 and early 2024—reaching a minimum of 56 days—a secondary peak of 65 days occurred in June 2025. The period concluded at 59 days in September 2026.
Overall, the operating activity patterns suggest a shift in the credit cycle. While the company managed to recover some efficiency after the late 2022 peak, the average collection period has generally settled at a higher level than the initial 51-day baseline, indicating a slightly longer average duration for payment receipts.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 111 | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Average receivable collection period | 59 | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | 170 | 177 | 173 | 166 | 170 | 169 | 159 | 156 | 160 | 172 | 164 | 163 | 169 | 163 | 159 | 162 | 137 | 136 | 132 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 187 | 180 | 173 | 174 | 178 | 186 | 177 | 161 | 164 | 153 | 155 | 148 | 153 | 160 | 155 | 146 | 134 | 145 | 143 | ||||||
| Amgen Inc. | 308 | 298 | 285 | 288 | 280 | 289 | 286 | 276 | 295 | 343 | 409 | 510 | 347 | 349 | 363 | 363 | 351 | 339 | 323 | ||||||
| Danaher Corp. | 167 | 172 | 150 | 148 | 155 | 155 | 150 | 142 | 155 | 153 | 150 | 156 | 163 | 157 | 157 | 148 | 147 | 152 | 147 | ||||||
| Eli Lilly & Co. | 562 | 555 | 521 | 553 | 540 | 532 | 469 | 418 | 441 | 419 | 392 | 395 | 354 | 360 | 367 | 325 | 280 | 284 | 268 | ||||||
| Johnson & Johnson | 244 | 247 | 239 | 238 | 246 | 240 | 228 | 226 | 236 | 233 | 222 | 218 | 211 | 232 | 220 | 209 | 196 | 198 | 192 | ||||||
| Merck & Co. Inc. | 187 | 195 | 206 | 214 | 229 | 230 | 212 | 205 | 215 | 221 | 219 | 207 | 203 | 206 | 200 | 182 | 177 | 181 | 199 | ||||||
| Pfizer Inc. | 297 | 284 | 305 | 311 | 334 | 308 | 298 | 288 | 306 | 252 | 242 | 218 | 196 | 206 | 167 | 135 | 160 | 155 | 151 | ||||||
| Regeneron Pharmaceuticals Inc. | 603 | 633 | 631 | 702 | 717 | 714 | 726 | 732 | 734 | 717 | 699 | 677 | 664 | 680 | 700 | 722 | 588 | 511 | 394 | ||||||
| Thermo Fisher Scientific Inc. | 148 | 149 | 149 | 148 | 156 | 153 | 148 | 142 | 150 | 144 | 142 | 142 | 146 | 146 | 145 | 145 | 148 | 157 | 164 | ||||||
| Vertex Pharmaceuticals Inc. | 502 | 427 | 444 | 435 | 430 | 406 | 379 | 340 | 327 | 296 | 286 | 272 | 271 | 252 | 238 | 215 | 194 | 193 | 188 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 111 + 59 = 170
2 Click competitor name to see calculations.
The analysis of the operating activity ratios reveals a consistent expansion of the operating cycle over the period from March 2022 to September 2026. The duration required to convert inventory and receivables into cash has increased, primarily driven by a lengthening inventory processing period.
- Average Inventory Processing Period
- A sustained upward trend is observed in the time required to process inventory. Starting at 81 days in March 2022, the period experienced a gradual increase, surpassing 100 days by March 2023 and reaching a peak of 115 days by June 2026. This indicates a deceleration in inventory turnover or a strategic increase in stock holdings over the observed timeframe.
- Average Receivable Collection Period
- The collection period exhibits relative stability compared to inventory processing, despite a moderate increase from the initial 51 days in March 2022. While fluctuations occur, the period generally remained within a range of 56 to 65 days for the majority of the analyzed period, suggesting a consistent efficiency in the credit and collection processes.
- Operating Cycle
- The total operating cycle reflects the combined impact of inventory and receivable periods, showing a clear trajectory of growth. The cycle expanded from 132 days in March 2022 to 170 days by September 2026, with a notable increase occurring between September and December 2022. The overall lengthening of the cycle is predominantly attributable to the increase in the average inventory processing period, which has outweighed the relative stability of receivable collection times.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Payables Payment Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | 6.66 | 9.22 | 9.52 | 8.72 | 7.66 | 10.65 | 8.47 | 7.50 | 7.49 | 12.57 | 10.69 | 11.81 | 9.90 | 9.06 | 8.99 | 6.25 | 11.22 | 11.89 | 11.43 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | 55 | 40 | 38 | 42 | 48 | 34 | 43 | 49 | 49 | 29 | 34 | 31 | 37 | 40 | 41 | 58 | 33 | 31 | 32 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | 95 | 90 | 91 | 72 | 85 | 89 | 70 | 54 | 61 | 73 | 60 | 69 | 70 | 64 | 73 | 90 | 69 | 72 | 78 | ||||||
| Bristol-Myers Squibb Co. | 110 | 103 | 108 | 94 | 107 | 140 | 104 | 94 | 106 | 120 | 117 | 111 | 97 | 108 | 114 | 109 | 96 | 107 | 112 | ||||||
| Danaher Corp. | 60 | 64 | 64 | 67 | 63 | 65 | 66 | 66 | 60 | 63 | 62 | 65 | 65 | 63 | 64 | 67 | 65 | 73 | 72 | ||||||
| Eli Lilly & Co. | 149 | 169 | 148 | 178 | 154 | 161 | 140 | 140 | 135 | 142 | 127 | 134 | 130 | 138 | 119 | 106 | 86 | 87 | 70 | ||||||
| Johnson & Johnson | 106 | 107 | 123 | 145 | 119 | 119 | 123 | 137 | 120 | 121 | 113 | 132 | 111 | 133 | 120 | 137 | 118 | 116 | 112 | ||||||
| Merck & Co. Inc. | 96 | 78 | 82 | 98 | 103 | 95 | 92 | 98 | 86 | 83 | 81 | 89 | 80 | 80 | 84 | 89 | 71 | 75 | 86 | ||||||
| Pfizer Inc. | 88 | 98 | 98 | 119 | 110 | 106 | 110 | 115 | 99 | 79 | 87 | 98 | 72 | 93 | 76 | 72 | 66 | 59 | 55 | ||||||
| Regeneron Pharmaceuticals Inc. | 173 | 180 | 163 | 163 | 158 | 129 | 129 | 146 | 94 | 110 | 137 | 122 | 106 | 116 | 136 | 138 | 98 | 91 | 68 | ||||||
| Thermo Fisher Scientific Inc. | 40 | 43 | 46 | 50 | 44 | 43 | 44 | 45 | 38 | 37 | 37 | 41 | 35 | 34 | 39 | 48 | 37 | 41 | 46 | ||||||
| Vertex Pharmaceuticals Inc. | 92 | 89 | 106 | 102 | 95 | 102 | 105 | 98 | 98 | 85 | 96 | 106 | 117 | 115 | 107 | 103 | 44 | 73 | 66 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.66 = 55
2 Click competitor name to see calculations.
An analysis of the short-term operating activity ratios reveals significant volatility in the management of accounts payable over the observed period. The average payables payment period exhibits a non-linear trend characterized by periodic spikes and subsequent contractions, which is mirrored inversely by the payables turnover ratio.
- Average Payables Payment Period Dynamics
- The payment period fluctuated between a minimum of 29 days in June 2024 and a maximum of 58 days in December 2022. Notable expansions in the duration of payment are observed in December 2022 (58 days), September 2024 (49 days), and September 2026 (55 days), suggesting intermittent extensions of credit terms with suppliers or strategic shifts in cash outflow timing.
- Payables Turnover Correlations
- The payables turnover ratio maintains a strict inverse relationship with the payment period. Peak efficiency in turnover was recorded in June 2024 at 12.57, which coincides with the shortest recorded payment window. The lowest turnover rates occurred in December 2022 (6.25) and September 2026 (6.66), reflecting periods where obligations were settled at a slower velocity.
- Temporal Patterns and Trends
- A pattern of cyclical volatility is evident. Following a period of relative stability in early 2022, a sharp increase in the payment period occurred in late 2022, followed by a steady decline from March 2023 through December 2023, where the period dropped from 41 to 31 days. A similar sequence of contraction and expansion is observed between 2024 and 2026, with the payment period frequently oscillating between 30 and 50 days.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cash Conversion Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 111 | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Average receivable collection period | 59 | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Average payables payment period | 55 | 40 | 38 | 42 | 48 | 34 | 43 | 49 | 49 | 29 | 34 | 31 | 37 | 40 | 41 | 58 | 33 | 31 | 32 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Cash conversion cycle1 | 115 | 137 | 135 | 124 | 122 | 135 | 116 | 107 | 111 | 143 | 130 | 132 | 132 | 123 | 118 | 104 | 104 | 105 | 100 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | 213 | 208 | 194 | 216 | 195 | 200 | 216 | 222 | 234 | 270 | 349 | 441 | 277 | 285 | 290 | 273 | 282 | 267 | 245 | ||||||
| Danaher Corp. | 107 | 108 | 86 | 81 | 92 | 90 | 84 | 76 | 95 | 90 | 88 | 91 | 98 | 94 | 93 | 81 | 82 | 79 | 75 | ||||||
| Eli Lilly & Co. | 413 | 386 | 373 | 375 | 386 | 371 | 329 | 278 | 306 | 277 | 265 | 261 | 224 | 222 | 248 | 219 | 194 | 197 | 198 | ||||||
| Johnson & Johnson | 138 | 140 | 116 | 93 | 127 | 121 | 105 | 89 | 116 | 112 | 109 | 86 | 100 | 99 | 100 | 72 | 78 | 82 | 80 | ||||||
| Merck & Co. Inc. | 91 | 117 | 124 | 116 | 126 | 135 | 120 | 107 | 129 | 138 | 138 | 118 | 123 | 126 | 116 | 93 | 106 | 106 | 113 | ||||||
| Pfizer Inc. | 209 | 186 | 207 | 192 | 224 | 202 | 188 | 173 | 207 | 173 | 155 | 120 | 124 | 113 | 91 | 63 | 94 | 96 | 96 | ||||||
| Regeneron Pharmaceuticals Inc. | 430 | 453 | 468 | 539 | 559 | 585 | 597 | 586 | 640 | 607 | 562 | 555 | 558 | 564 | 564 | 584 | 490 | 420 | 326 | ||||||
| Thermo Fisher Scientific Inc. | 108 | 106 | 103 | 98 | 112 | 110 | 104 | 97 | 112 | 107 | 105 | 101 | 111 | 112 | 106 | 97 | 111 | 116 | 118 | ||||||
| Vertex Pharmaceuticals Inc. | 410 | 338 | 338 | 333 | 335 | 304 | 274 | 242 | 229 | 211 | 190 | 166 | 154 | 137 | 131 | 112 | 150 | 120 | 122 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 111 + 59 – 55 = 115
2 Click competitor name to see calculations.
The Cash Conversion Cycle exhibits a general expansion from early 2022 through late 2026, indicating a prolonged duration between the initial outlay of cash for inventory and the final receipt of cash from sales. While the cycle began at 100 days in March 2022, it reached a peak of 143 days in June 2024 before concluding at 115 days by September 2026.
- Average Inventory Processing Period
- A consistent upward trajectory is observed in inventory management. The processing period rose from 81 days in the first half of 2022 to a peak of 115 days in June 2026. This persistent increase suggests a slowing of inventory turnover, which may be attributed to strategic stockpiling or a decrease in sales velocity relative to inventory holdings.
- Average Receivable Collection Period
- Receivable collections remained relatively stable, though they shifted slightly higher over the observed period. After an initial low of 51 days in March 2022, the period fluctuated primarily between 56 and 65 days. This stability indicates a consistent application of credit policies and a steady rate of collection efficiency.
- Average Payables Payment Period
- Payment to suppliers is characterized by significant volatility. The period experienced sharp fluctuations, dropping to 29 days in June 2024 and spiking to 58 days in December 2022 and 55 days in September 2026. These oscillations suggest inconsistent timing in supplier payments or an opportunistic approach to managing short-term liabilities.
The overall lengthening of the cash conversion cycle is primarily driven by the increase in the inventory processing period, which has offset the benefits of occasional extensions in the payables payment period. Although the cycle contracted slightly in the final quarters of 2026, the operational efficiency regarding cash recovery remains lower than the levels observed at the start of 2022.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?